促销时间表 Arrowhead Pharmaceuticals, Inc.
先进的时间表
简单图表
关于公司
Arrowhead Pharmaceuticals, Inc. разрабатывает лекарства для лечения трудноизлечимых заболеваний в Соединенных Штатах.
更多详情P/E | 39.11 |
---|---|
P/S | 15.75 |
P/BV | 10.89 |
EV/EBITDA | 37.13 |
EBITDA | 0.0656 |
Цена ао | 19.02 |
Сайт | http://arrowheadpharma.com |
Число акций ао | 0.10675 млрд |
Выручка | 0.1688 |
Див.доход ао | 0 |
ISIN | US04280A1007 |
Валюта | usd |
IPO date | 1993-06-16 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
每日价格变化: | 0% (18.79) |
---|---|
每周价格变化: | +1.02% (18.6) |
每月价格变化: | -6.52% (20.1) |
3个月内价格变化: | -20.31% (23.58) |
六个月内的价格变化: | -21.45% (23.92) |
每年价格变化: | -28.17% (26.16) |
3年内价格变化: | -71.66% (66.3) |
5年内价格变化: | -67.1% (57.11) |
年初以来价格变化: | -39.39% (31) |
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
交易日期 | 披露日期 | 内幕 | 类型 | 价格 | 体积 | 数量 | 分享最多, % | 之后分享, % | 文档 |
---|---|---|---|---|---|---|---|---|---|
20.03.2024 | 20.03.2024 | Lu Hongbo Director |
购买 | 27.5 | 27 500 | 1000 | 0 | 0 | 关联 |
19.03.2024 | 20.03.2024 | Lu Hongbo Director |
购买 | 28 | 28 000 | 1000 | 0 | 0 | 关联 |
18.03.2024 | 20.03.2024 | Lu Hongbo Director |
购买 | 27.49 | 27 490 | 1000 | 0 | 0 | 关联 |
12.01.2024 | 17.01.2024 | Hamilton James C Chief Discovery/Trans Medicine |
销售 | 36.89 | 292 907 | 7940 | 0 | -0.01 | 关联 |
11.01.2024 | 16.01.2024 | Vakiener Victoria Director |
销售 | 38.1 | 179 832 | 4720 | 0 | 0 | 关联 |
11.01.2024 | 16.01.2024 | Ferrari Mauro Director |
销售 | 38.06 | 119 775 | 3147 | 0 | 0 | 关联 |
11.01.2024 | 16.01.2024 | Waddill William D. Director |
销售 | 38.07 | 149 767 | 3934 | 0 | 0 | 关联 |
11.01.2024 | 16.01.2024 | GIVEN DOUGLAS B Director |
销售 | 38.06 | 110 793 | 2911 | 0 | 0 | 关联 |
05.01.2024 | 05.01.2024 | Hamilton James C Chief Discovery/Trans Medicine |
销售 | 35.18 | 1 130 790 | 32143 | 0 | -0.03 | 关联 |
03.01.2024 | 05.01.2024 | Hamilton James C Chief Discovery/Trans Medicine |
销售 | 32.19 | 202 797 | 6300 | 0 | -0.01 | 关联 |
04.05.2023 | 05.05.2023 | Anzalone Christopher Richard Chief Executive Officer |
销售 | 39.52 | 1 976 000 | 50000 | 0 | -0.05 | 关联 |
04.05.2023 | 05.05.2023 | Anzalone Christopher Richard Chief Executive Officer |
购买 | 2.01 | 100 500 | 50000 | 0 | 0.05 | 关联 |
03.05.2023 | 05.05.2023 | Anzalone Christopher Richard Chief Executive Officer |
销售 | 39.14 | 2 149 880 | 54928 | 0 | -0.05 | 关联 |
03.05.2023 | 05.05.2023 | Anzalone Christopher Richard Chief Executive Officer |
购买 | 2.01 | 110 405 | 54928 | 0 | 0.05 | 关联 |
03.03.2023 | 06.03.2023 | OLUKOTUN ADEOYE Y Director |
销售 | 32.65 | 370 578 | 11350 | 0 | -0.01 | 关联 |
21.11.2022 | 22.11.2022 | San Martin Javier Chief Medical Officer |
销售 | 29.99 | 584 805 | 19500 | 0 | -0.02 | 关联 |
07.07.2022 | 11.07.2022 | Anzalone Christopher Richard Chief Executive Officer |
购买 | 14.54 | 36 365 | 2501 | 0 | 0 | 关联 |
05.01.2022 | 07.01.2022 | O'Brien Patrick General Counsel |
销售 | 61.72 | 2 005 900 | 32500 | 0 | -0.03 | 关联 |
15.12.2021 | 17.12.2021 | Anzalone Christopher Richard Chief Executive Officer |
销售 | 67.56 | 4 053 600 | 60000 | 0 | -0.06 | 关联 |
12.01.2021 | 12.01.2021 | Myszkowski Kenneth Allen Chief Financial Officer |
销售 | 81 | 116 721 | 1441 | 0 | 0 | 关联 |
11.01.2021 | 12.01.2021 | Myszkowski Kenneth Allen Chief Financial Officer |
销售 | 81.02 | 939 589 | 11597 | 0 | -0.01 | 关联 |
07.01.2021 | 08.01.2021 | Hassard James Chief Commercial Officer |
销售 | 75 | 1 171 880 | 15625 | 0 | -0.02 | 关联 |
06.01.2021 | 07.01.2021 | Hamilton James C Senior Vice President |
销售 | 72.48 | 1 404 300 | 19375 | 0 | -0.02 | 关联 |
06.01.2021 | 07.01.2021 | Myszkowski Kenneth Allen Chief Financial Officer |
销售 | 72.44 | 2 218 480 | 30625 | 0 | -0.03 | 关联 |
06.01.2021 | 07.01.2021 | O'Brien Patrick General Counsel |
销售 | 72.41 | 1 810 250 | 25000 | 0 | -0.03 | 关联 |
05.01.2021 | 07.01.2021 | Hamilton James C Senior Vice President |
销售 | 72.53 | 1 405 270 | 19375 | 0 | -0.02 | 关联 |
04.01.2021 | 05.01.2021 | Waddill William D. Director |
销售 | 76.08 | 285 300 | 3750 | 0 | 0 | 关联 |
19.11.2020 | 20.11.2020 | San Martin Javier Chief Medical Officer |
销售 | 69.39 | 1 353 100 | 19500 | 0 | -0.02 | 关联 |
机构 | 体积 | 分享, % |
---|---|---|
Blackrock Inc. | 13303757 | 10.74 |
Vanguard Group Inc | 10672076 | 8.61 |
State Street Corporation | 6825111 | 5.51 |
FMR, LLC | 3371268 | 2.72 |
JP Morgan Chase & Company | 2751048 | 2.22 |
Geode Capital Management, LLC | 2326876 | 1.88 |
Invesco Ltd. | 2306308 | 1.86 |
Credit Suisse Ag/ | 1745342 | 1.41 |
Slate Path Capital, LP | 1329000 | 1.07 |
Norges Bank Investment Management | 1321927 | 1.07 |
导师 | 职称 | 支付 | 出生年份 |
---|---|---|---|
Mr. Kenneth A. Myszkowski | Chief Financial Officer | 834.34k | 1966 (58 年) |
Mr. Howard Lovy | Director of Communications | N/A | |
Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | N/A | |
Dr. Mark Seefeld | Head of Toxicology & VP | N/A | 1954 (70 年) |
Dr. Christopher R. Anzalone Ph.D. | CEO, President & Director | 1.6M | 1969 (55 年) |
Dr. James C. Hamilton M.D., MBA | Chief of Discovery & Translational Medicine | 762.14k | 1978 (46 年) |
Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | N/A | |
Ms. Tracie Oliver | Chief Commercial Officer | 449.58k | 1962 (62 年) |
Dr. Bruce D. Given M.D. | Chief Medical Scientist | 486.31k | 1954 (70 年) |
Mr. Patrick O'Brien J.D., PharmD | COO, General Counsel & Secretary | 1964 (60 年) |
地址: United States, Pasadena, CA , 177 East Colorado Boulevard - 在 Google 地图中打开, 打开 Yandex 地图
网站: http://arrowheadpharma.com
网站: http://arrowheadpharma.com